BioRestorative Therapies Approves 2025 Executive Bonuses and Updates Compensation Disclosures

On May 1, 2026, BioRestorative Therapies, Inc. filed an 8-K reporting that its Compensation Committee approved cash bonuses for the company's executive officers for the fiscal year ended December 31, 2025. The filing includes an updated Summary Compensation Table for the Named Executive Officers. CEO Lance Alstodt was awarded a discretionary bonus of $300,000 for 2025 services, bringing his total 2025 compensation to $2,409,167, which included $1,512,500 in option awards. Francisco Silva, VP of Research and Development, received a $287,500 bonus with total compensation of $2,322,916. CFO Robert Kristal was awarded a $140,000 bonus, resulting in total compensation of $801,750. These 2025 bonuses are scheduled to be paid in 2026. The report provides a year-over-year comparison with 2024 compensation figures, noting that the prior year's bonuses were paid in 2025. No other material corporate developments or clinical updates were disclosed in this filing.